Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + gefitinib + gemcitabine
- Development stage
- Phase 3
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination involves **carboplatin**, a platinum-based chemotherapy drug; **gefitinib**, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor; and **gemcitabine**, a nucleoside analog used in chemotherapy. The combination is used to treat non-small cell lung cancer (NSCLC), particularly in never smokers with advanced disease. Carboplatin and gemcitabine work by interfering with DNA replication in rapidly dividing cancer cells, while gefitinib blocks the EGFR signaling pathway, which is often overactive in certain cancers.
- Other names
- Gemcitabine-Carboplatin-Gefitinib (GCI)
02
Targets
Beyond the preview
Go deeper on carboplatin + gefitinib + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + gefitinib + gemcitabine.